Incyte (INCY - Get Report) is a drug discovery and development company, focused on developing small molecule drugs to treat serious unmet medical needs. This stock is trading up 6% at $14.43 in recent trading.
Today's Volume: 1.2 million sharesAverage Volume: 2 million shares Volume % Change: 50% From a technical standpoint, INCY has started to spike back above its 50-day moving average of $13.75 on decent volume. Market players should now watch for a sustained high-volume move and close above its next significant overhead resistance levels at 14.72 to $14.75. Look for volume above those levels that tracks in close to or above 2 million. If we get that action, then look for this stock to re-test $15.49 to $15.94 (its 200-day) in the near future. Incyte shows up on a list of 10 Biotech Stocks Loved and Hated by the Pros.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts